drugset / Trial / NCT04258410

Quercetin for Cardio-Skeletal Muscle Health and Estrogen Deficiency

NCT04258410

RandomizedParallel-groupQuadruple-blindPrevention

Summary

Double blind randomized controlled parallel pilot trial of Quercetin vs placebo oral administration in 24 postmenopausal women. The study team will conduct a feasibility pilot in preparation for a larger efficacy trial that will test the protective effects of quercetin against cardiac and skeletal muscle dysfunction and changes in structure induced by estrogen loss and potential mechanistic pathways in post-menopausal women at risk of heart failure with preserved ejection fraction (HFPEF).

Timeline

Start
2022-09
Primary completion
2023-12
Completion
2024-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Quercetin Small molecule 500 mg Oral

Indications

No indication recorded.